Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group. Dickstein Y, et al. Among authors: leibovici l. Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988. Clin Infect Dis. 2019. PMID: 30462182 Clinical Trial.
Impact of the 2019 Food and Drug Administration Guidance for Uncomplicated Urinary Tract Infection on Treatment Response Rates: A Reanalysis of a Clinical Trial of Nitrofurantoin vs Fosfomycin.
Grant R, Büchler A, Flight W, Huang C, Ferrinho D, Janmohamed S, Mulgirigama A, Godycki-Cwirko M, Leibovici L, Huttner A, Harbarth S. Grant R, et al. Among authors: leibovici l. Open Forum Infect Dis. 2023 Nov 4;10(11):ofad557. doi: 10.1093/ofid/ofad557. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023546 Free PMC article.
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.
Kaye KS, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Paul M, Roilides E, Rybak M, Samarkos M, Sims M, Tancheva D, Tsiodras S, Kett D, Patel G, Calfee D, Leibovici L, Power L, Munoz-Price S, Stevenson K, Susick L, Latack K, Daniel J, Chiou C, Divine GW, Ghazyaran V, Pogue JM. Kaye KS, et al. Among authors: leibovici l. NEJM Evid. 2023 Jan;2(1):10.1056/evidoa2200131. doi: 10.1056/evidoa2200131. Epub 2022 Dec 6. NEJM Evid. 2023. PMID: 37538951 Free PMC article.
Which trials do we need?
Leibovici L. Leibovici L. Clin Microbiol Infect. 2024 Apr 5:S1198-743X(24)00171-X. doi: 10.1016/j.cmi.2024.04.002. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38583521 No abstract available.
Quality, availability and suitability of antimicrobial stewardship guidance: a multinational qualitative study.
Linde-Ozola Z, Classen AY, Giske CG, Göpel S, Eliakim-Raz N, Semret M, Simonsen GS, Vehreschild JJ, Jørgensen SB, Kessel J, Kleppe LKS, Oma DH, Vehreschild MJGT, Vilde A, Dumpis U; PILGRIM study group. Linde-Ozola Z, et al. JAC Antimicrob Resist. 2024 Mar 14;6(2):dlae039. doi: 10.1093/jacamr/dlae039. eCollection 2024 Apr. JAC Antimicrob Resist. 2024. PMID: 38486662 Free PMC article.
476 results